GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Effective Interest Rate on Debt %

MedMira (MedMira) Effective Interest Rate on Debt % : 9.91% (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Effective Interest Rate on Debt %?

Effective Interest Rate on Debt % is the usage rate that a borrower actually pays on a debt. It is calculated as the positive value of Interest Expense divided by its average total debt. Total debt equals to Long-Term Debt & Capital Lease Obligation plus Short-Term Debt & Capital Lease Obligation. MedMira's annualized positive value of Interest Expense for the quarter that ended in Jan. 2024 was $0.66 Mil. MedMira's average total debt for the quarter that ended in Jan. 2024 was $6.70 Mil. Therefore, MedMira's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2024 was 9.91%.


MedMira Effective Interest Rate on Debt % Historical Data

The historical data trend for MedMira's Effective Interest Rate on Debt % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Effective Interest Rate on Debt % Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Effective Interest Rate on Debt %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.01 6.99 5.78 5.47 9.99

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Effective Interest Rate on Debt % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.57 5.44 22.05 7.73 9.91

Competitive Comparison of MedMira's Effective Interest Rate on Debt %

For the Biotechnology subindustry, MedMira's Effective Interest Rate on Debt %, along with its competitors' market caps and Effective Interest Rate on Debt % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Effective Interest Rate on Debt % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Effective Interest Rate on Debt % distribution charts can be found below:

* The bar in red indicates where MedMira's Effective Interest Rate on Debt % falls into.



MedMira Effective Interest Rate on Debt % Calculation

MedMira's annualized Effective Interest Rate on Debt % for the fiscal year that ended in Jul. 2023 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (A: Jul. 2022 )+Total Debt  (A: Jul. 2023 ))/ count )
=-1  *  -0.671/( (6.415+7.017)/ 2 )
=-1  *  -0.671/6.716
=9.99 %

where

Total Debt  (A: Jul. 2022 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.583 + 4.832
=6.415

Total Debt  (A: Jul. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.238 + 4.779
=7.017

MedMira's annualized Effective Interest Rate on Debt % for the quarter that ended in Jan. 2024 is calculated as

Effective Interest Rate on Debt %
=-1  *  Interest Expense/( (Total Debt  (Q: Oct. 2023 )+Total Debt  (Q: Jan. 2024 ))/ count )
=-1  *  -0.664/( (6.752+6.651)/ 2 )
=-1  *  -0.664/6.7015
=9.91 %

where

Total Debt  (Q: Oct. 2023 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=2.144 + 4.608
=6.752

Total Debt  (Q: Jan. 2024 )
=Long-Term Debt & Capital Lease Obligation + Short-Term Debt & Capital Lease Obligation
=1.969 + 4.682
=6.651

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Effective Interest Rate on Debt %, the Interest Expense of the last fiscal year and the average total debt over the fiscal year are used. In calculating the quarterly data, the Interest Expense data used here is four times the quarterly (Jan. 2024) interest expense data. Effective Interest Rate on Debt % is displayed in the 30-year financial page.


MedMira  (OTCPK:MMIRF) Effective Interest Rate on Debt % Explanation

Effective Interest Rate on Debt % measures the usage rate that a borrower actually pays on a debt.


MedMira Effective Interest Rate on Debt % Related Terms

Thank you for viewing the detailed overview of MedMira's Effective Interest Rate on Debt % provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Industry
Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Announces Product Update

By GlobeNewswire GlobeNewswire 12-31-2020

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

MedMira Reports 2019 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 11-29-2019

MedMira Introduces VYRA TriDemic

By ACCESSWIRE ACCESSWIRE 12-30-2022

MedMira Reports FY2021 Fourth Quarter and Year End Financial Results

By GlobeNewswire GlobeNewswire 12-01-2021

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023